⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75552 | 0.61 | — | — | |
| SCHEMBL308103 | 0.61 | — | — | |
| SCHEMBL6364430 | 0.58 | — | — | |
| SCHEMBL2011308 | 0.57 | — | — | |
| SCHEMBL293677 | 0.57 | — | — | |
| SCHEMBL1035336 | 0.56 | — | — | |
| SCHEMBL828805 | 0.56 | — | — | |
| SCHEMBL195173 | 0.56 | — | — | |
| SCHEMBL74000 | 0.53 | — | — | |
| SCHEMBL616019 | 0.51 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991215-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | Cenix Bioscience GmbH (DE) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007101710-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2007-09-13 | — | — | WO | disclosed |